HighTower Advisors LLC Takes $494,000 Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

HighTower Advisors LLC bought a new position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 10,449 shares of the company’s stock, valued at approximately $494,000.

A number of other large investors have also recently added to or reduced their stakes in the company. Values First Advisors Inc. acquired a new position in Kymera Therapeutics in the 3rd quarter valued at $61,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in Kymera Therapeutics by 27.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company’s stock worth $114,000 after acquiring an additional 504 shares in the last quarter. Public Employees Retirement Association of Colorado bought a new stake in Kymera Therapeutics during the 2nd quarter valued at $139,000. Quest Partners LLC grew its holdings in Kymera Therapeutics by 1,402.0% during the second quarter. Quest Partners LLC now owns 5,212 shares of the company’s stock worth $156,000 after buying an additional 4,865 shares in the last quarter. Finally, XTX Topco Ltd purchased a new stake in Kymera Therapeutics in the 2nd quarter valued at about $201,000.

Wall Street Analyst Weigh In

KYMR has been the subject of a number of analyst reports. BMO Capital Markets initiated coverage on Kymera Therapeutics in a report on Friday, December 6th. They issued a “market perform” rating and a $55.00 price target for the company. Guggenheim raised their target price on shares of Kymera Therapeutics from $45.00 to $52.00 and gave the stock a “buy” rating in a report on Friday, November 1st. Leerink Partners reiterated an “outperform” rating and set a $60.00 target price on shares of Kymera Therapeutics in a report on Monday, September 9th. Leerink Partnrs upgraded Kymera Therapeutics to a “strong-buy” rating in a report on Monday, September 9th. Finally, Truist Financial restated a “buy” rating and issued a $53.00 price target (down from $54.00) on shares of Kymera Therapeutics in a research note on Friday, November 1st. Four equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $53.88.

Kymera Therapeutics Stock Up 3.9 %

NASDAQ:KYMR opened at $40.66 on Friday. The firm’s fifty day simple moving average is $46.00 and its 200-day simple moving average is $43.14. The stock has a market cap of $2.63 billion, a PE ratio of -17.38 and a beta of 2.16. Kymera Therapeutics, Inc. has a fifty-two week low of $22.35 and a fifty-two week high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR) last announced its earnings results on Thursday, October 31st. The company reported ($0.82) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.01. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The company had revenue of $3.74 million during the quarter, compared to analysts’ expectations of $10.34 million. During the same quarter in the previous year, the business posted ($0.90) earnings per share. The firm’s quarterly revenue was down 20.9% compared to the same quarter last year. Equities analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.